Alzheimer's Disease Market Research Reports & Industry Analysis
A gradual loss of neurons later in adulthood does not result in significant alteration in brain function during the usual life span. However, the older one gets, the greater the neurologic impairment. Excessive neuronal degeneration in adulthood is called Alzheimer’s disease or senile dementia and is distinguished from the normal changes in aging. Alzheimer’s disease is a progressive disease which results in death of the brain cells causing memory lapses, behavioral issues, and disruption of thinking processes. The disease is considered fatal. Age and generic inheritance are the two key risk factors for developing Alzheimer’s disease. These are also risk factors that are not preventable. However, other preventable risk factors have been linked to the development of AD, including environment, diet, and overall general health. A combination of risk factors is often responsible for the disease.
Alzheimer’s disease is estimated to affect up to 6% of the population over 65. Life expectancy has been increasing around the world due to advances in healthcare, medical research, sanitation, and nutrition. This provides a setting for a higher number of Alzheimer’s disease patients in the future as the population continues to add years to their life.
Alzheimer's Disease Industry Research & Market Reports
-
Global Lewy Body Dementia Treatment Market Size study, by Drug Type (Cholinesterase Inhibitors, Antipsychotic Drugs, Antidepressants, Benzodiazepine, Modafinil) by Application Type (Parkinson’s Disease, Alzheimer’s Disease) by Mode of Purchase (Prescription and Over the Counter) by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others) and Regional Forecasts 2022-2028
... Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others) and Regional Forecasts 2022-2028 Global Lewy Body Dementia Treatment Market is valued approximately USD XX billion in 2021 and is anticipated to grow with a ... Read More
-
Global Johnson Neuroectodermal Syndrome Market Size study, by Drug Class (Immunomodulators, Interferons, Decarboxylase Inhibitors, Dopamine Agonists and Others) by Disease Indication (Multiple Sclerosis, Parkinson’s Disease, Alzheimer's Disease, Spinal Muscular Atrophy (SMA) and Others), by Route of Administration (Oral, Injection, Transdermal), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy and Online Pharmacy) and Regional Forecasts 2022-2028
... of Administration (Oral, Injection, Transdermal), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy and Online Pharmacy) and Regional Forecasts 2022-2028 Global Johnson Neuroectodermal Syndrome Market is valued approximately USD XX billion in 2022 and is anticipated ... Read More
-
Brain Disease Modalities and Software Market - A Global and Regional Analysis: Focus on Product, Indication, Patient Type, End User, and Regional Analysis - Analysis and Forecast, 2022-2031
... and Software Market Segmentation Indication - Brain Diseases (Brain and Central Nervous System Cancer, Idiopathic Epilepsy, Ischemic stroke, and Other Brain Diseases) and Neurodegenerative Diseases (Alzheimer’s Disease, Multiple Sclerosis, Parkinson’s Disease, Motor Neuron Disease, and ... Read More
-
Global Alzheimer Drugs Market (2022 Edition) – Analysis By Drug Class (Cholinergic, Memantine, Combined Drugs, Others), Distribution Channel, By Region, By Country: Market Insights, Pipeline and Forecast with Impact of Covid-19 (2022-2027)
... to Azoth Analytics research report, the Global Alzheimer's Drugs Market was valued at USD 6537.0 Million in the year 2021. Diabetes, obesity, heart diseases and high blood pressure (BP), in confluence with sedentary lifestyles, unhealthy ... Read More
-
5G in Healthcare Market Size, Share & Trends Analysis By Component, By Application, By End User, Regional Outlook, Competitive Strategies and Segment Forecasts to 2030
... 3.9 Bn by 2030 According to SPER Market Research, the 5G in healthcare market estimated to reach USD 3.9 Bn by 2030 with a CAGR of 69.8%. Technologies such as Telehealth and robotics services are ... Read More
-
Neurodegenerative Disease Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)
... 44.90 billion in 2026, with a CAGR of 2.30% over the forecast period. The COVID-19 impact on the Neurodegenerative Disease market is expected to be significant as the pandemic has impacted the workflows of clinical ... Read More
-
Alzheimer's disease (AD) - Epidemiology Forecast to 2032
... Spain, Italy, France, and the United Kingdom), and Japan. Geographies Covered • The United States • EU5 (Germany, France, Italy, Spain, and the United Kingdom) • Japan Study Period: 2019-2032 Alzheimer's disease (AD) Understanding The ... Read More
-
Global Alzheimer's Disease Market and Competitive Landscape – 2017
... sales, market forecast, product forecasts, and market shares. This study accurately estimates and forecast Alzheimer's Disease market size and drug sales. This research also provides insights into Alzheimer's Disease epidemiology and late stage pipeline. The ... Read More
-
Potential "Pipeline Disruptors" - New Products That Will Drive The Future Pharmaceutical Market
... six areas are expected to show the strongest pipeline impact and candidates are likely to replace current therapies. The market is evaluated for 2015 and 2016 with forecast data provided through 2022. Forecast data were ... Read More
Research Assistance
